NeuroVive, OnCore Biopharma deal

OnCore Biopharma received exclusive, worldwide rights to develop and commercialize NeuroVive's preclinical sangamide-based cyclophilin inhibitors to treat HBV infection. NeuroVive will receive an undisclosed upfront payment, plus milestones worth up to $150 million, plus royalties. OnCore plans to start clinical testing of lead candidate, NVP018, next year. ...